Royalty Pharma plc filed its Form 10-Q for the quarterly period ended June 30, 2026 with the U.S. Securities and Exchange Commission on August 5, 2026, reporting total income and other revenues of $674.1 million for the three months ended June 30, 2026.

Key Highlights

  • Total income and other revenues: $674,141 thousand for the three months ended June 30, 2026, compared to $578,665 thousand for the same period in 2025.
  • Income from financial royalty assets: $638,027 thousand for Q2 2026, up from $550,418 thousand in Q2 2025.
  • Six-month total income and other revenues: $1,304,717 thousand for the six months ended June 30, 2026, versus $1,146,912 thousand for the same period in 2025.
  • Total assets: $19,819,771 thousand as of June 30, 2026, compared to $19,620,780 thousand as of December 31, 2025.
  • Long-term debt: $8,581,892 thousand as of June 30, 2026.
  • Shares outstanding: As of July 31, 2026, 445,277,344 Class A ordinary shares and 129,723,860 Class B ordinary shares were outstanding.
  • Cash and cash equivalents: $811,986 thousand as of June 30, 2026, up from $618,696 thousand as of December 31, 2025.

Royalty Pharma's Balance Sheet and Revenue Trends Through June 2026

According to the filing, Royalty Pharma plc (NASDAQ: RPRX) reported total income and other revenues of $674,141 thousand for the three months ended June 30, 2026, compared to $578,665 thousand for the three months ended June 30, 2025. Income from financial royalty assets, the company's primary revenue line, was $638,027 thousand in Q2 2026 versus $550,418 thousand in Q2 2025. Other royalty income and revenues contributed $36,114 thousand in Q2 2026, compared to $28,247 thousand in Q2 2025.

For the six months ended June 30, 2026, the filing reported total income and other revenues of $1,304,717 thousand, up from $1,146,912 thousand for the same period in 2025. The company's condensed consolidated balance sheet as of June 30, 2026 showed total assets of $19,819,771 thousand and total liabilities of $10,034,057 thousand, resulting in total shareholders' equity of $9,785,714 thousand. Financial royalty assets, net, were $16,192,717 thousand, compared to $16,208,482 thousand as of December 31, 2025.

The filing also disclosed a provision for changes in expected cash flows from financial royalty assets of $268,216 thousand for Q2 2026, compared to a negative provision (income) of $203,938 thousand in Q2 2025. The company noted its 2025 internalization of its manager among the factors referenced in its forward-looking statement cautionary language. The filing identifies itself as a large accelerated filer incorporated in England and Wales, with principal executive offices located at 110 East 59th Street, New York, New York 10022.

What Was Disclosed

Royalty Pharma plc filed its quarterly report covering the period ended June 30, 2026, disclosing income statements, balance sheet data, share counts, and operating expense details for the three- and six-month periods ended June 30, 2026 and 2025.